Michael Scolaro

Michael Scolaro

Nov 29, 2017

Group 6 Copy 186
1
References
  • 1. https://www.ncbi.nlm.nih.gov/pubmed/26558876
  • 2. https://www.ncbi.nlm.nih.gov/pubmed/26558876
Please wait...

About This Project

We hypothesize that targeted delivery of Curcumin to antigen presenting cells in the immune system can suppress tumor growth for a variety of cancers. This study will examine tumor responses to Curcumin in a colon cancer mouse model when given alone or in combination with an FDA-approved immune Checkpoint Inhibitor. Positive results will lead to Fast-Track FDA applications for human and companion pet animal cancer trials.

Blast off!

Browse Other Projects on Experiment

Related Projects

Can perfluorocarbon liquids remove benzo(a)pyrene, a model carcinogen from cells?

Lung cancer is the single largest cause of cancer mortality, accounting for about 19% of all cancer deaths...

Targeting the Hypoxic Response in Multiple Myeloma Cells Engrafted in the Bone Marrow

Multiple myeloma (MM) is a cancer of the bone marrow made up of plasma cells (a type of antibody-producing...

Identification of Pancreatic Cancer Specific Tumor Markers for Early Detection

Pancreatic cancer is the third leading cause of cancer-related death in the US, and expected to become the second...

Backer Badge Funded